Literature DB >> 9270437

Glottic-supraglottic barrier: fact or fantasy?

J A Kirchner1.   

Abstract

An anatomic structure that might act as a barrier between the glottic and supraglottic areas has never been demonstrated in whole organ serial section studies. Nevertheless, most squamous cell carcinomas arising on the supraglottic mucosa remain confined above the ventricle, and this fact is reflected in the high rate of local control obtained by surgeons performing horizontal supraglottic laryngectomy: 80.6% to 98%. Whole organ sections of laryngectomy specimens suggest that a tumor situated above and below the glottic level may have arrived there not by crossing the ventricle, but by encircling it. In so doing, part of the tumor is visible posterior to the ventricle or on the arytenoid cartilage-a finding that contraindicates conventional supraglottic laryngectomy, with or without limited mobility of the true vocal cord.

Entities:  

Mesh:

Year:  1997        PMID: 9270437     DOI: 10.1177/000348949710600816

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  3 in total

1.  Oncological outcome after CO2 laser cordectomy for early-stage glottic carcinoma.

Authors:  C Bocciolini; L Presutti; P Laudadio
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Endoscopic supraglottic laryngectomy: a proposal for a classification by the working committee on nomenclature, European Laryngological Society.

Authors:  Marc Remacle; Anastasios Hantzakos; Hans Eckel; Anne-Sophie Evrard; Patrick J Bradley; Dominique Chevalier; Vojko Djukic; Marco de Vincentiis; Gerhard Friedrich; Jan Olofsson; Giorgio Peretti; Miquel Quer; Jochen Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-01-08       Impact factor: 2.503

3.  Preservation of laryngeal function improves outcomes of patients with hypopharyngeal carcinoma.

Authors:  Tong Jin; Xuezhong Li; Dapeng Lei; Dayu Liu; Qiuan Yang; Guojun Li; Xinliang Pan
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-10       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.